-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $222 at Guggenheim
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
-
-
-
-
-
-
-
Morgan Stanley tracks prescription trends for US neurology drugs
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $176 at Wedbush
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $185 at Morgan Stanley
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX) Following Reports of Soleno Acquisition
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Lowered to $140 at Truist Securities
-
446,467 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

